MRK and TERN Related Headlines
Go Back- Merck completes $5.8 billion acquisition of Terns Pharmaceuticals
- Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
- Merck clears HSR waiting period for $53 per share Terns acquisition
- Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
- Merck launches tender offer to acquire Terns Pharmaceuticals for $53 per share
- Merck launches tender offer to acquire Terns Pharmaceuticals for $53 per share
- Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
- Truist Securities Downgrades Terns Pharmaceuticals (TERN) to Hold
- Mizuho Downgrades Terns Pharmaceuticals (TERN) to Neutral on Merck acquisition
- TD Cowen Downgrades Terns Pharmaceuticals (TERN) to Hold
- H.C. Wainwright Downgrades Terns Pharmaceuticals (TERN) to Neutral
- Truist Securities stays Buy on Terns Pharmaceuticals (TERN) as Merck acquires 'for a steal'
- Merck to buy oncology firm Terns Pharmaceuticals in $6.7 billion deal
- Merck to acquire Terns Pharmaceuticals for $6.7 billion
- Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
- Merck (MRK) Nears $6b Deal To Buy Terns Pharma (TERN) - FT
MRK and TERN Related Press Releases
Go Back- Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
- Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
- Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
- Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
